Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SUBLOCADE Clear all
Active, not recruiting Phase 2Phase 3 Interventional

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

NCT04408313
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
XR-B, XR-NTX
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Phase 4 Interventional Results available

SUBLOCADE Rapid Initiation Study

NCT03993392
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
TM buprenorphine, SUBLOCADE
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 30, 2026, 4:44 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone

NCT00000243
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Phase 3 Interventional

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

NCT01114308
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant), placebo implant, Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Los Angeles, California • National City, California • Oceanside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Phase 2Phase 3 Interventional

EXHIT ENTRE Comparative Effectiveness Trial

NCT04345718
View directory record Official record
Conditions
Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Extended Release Buprenorphine, Treatment as Usual
Drug
Lead sponsor
Gavin Bart
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

NCT03188185
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, ALKS 5461 Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Abuse Liability of Suboxone Versus Subutex

NCT00710385
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Heroin, Naloxone, Low Bup Dose, High Bup Dose, Low Bup/Nal Dose, High Bup/Nal Dose, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 30, 2026, 4:44 AM EDT
Completed No phase listed Observational

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

NCT03718104
View directory record Official record
Conditions
Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk, Alcohol Use Disorder
Interventions
Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis, Breast milk analysis
Other · Genetic
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Carrboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Phase 2 Interventional Results available

Cannabidiol in the Treatment of Opioid Use Disorder

NCT06206291
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Placebo, Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg
Drug
Lead sponsor
Yasmin Hurd
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 30, 2026, 4:44 AM EDT
Recruiting Phase 2 Interventional

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

NCT05778591
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Buprenorphine 0.15 MG [Belbuca]
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Phase 3 Interventional Results available

4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans

NCT02891798
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone), Bupivacaine Only (control arm)
Drug
Lead sponsor
Brian Williams
Federal
Eligibility
18 Years to 85 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 30, 2026, 4:44 AM EDT
Recruiting Not applicable Interventional

Technology-Enhanced Therapy vs. Medication Monitoring for Buprenorphine Retention in Pregnant Persons

NCT06999811
View directory record Official record
Conditions
Opioid Use Disorder, Pregnancy
Interventions
Empowering Pregnant Women and People Receiving medications for opioid use disorder (EMPWR), Medication monitoring (control)
Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 30, 2026, 4:44 AM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1

NCT00000326
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Heroin Dependence
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain

NCT00312572
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 85 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Not applicable Interventional

Incentivizing Buprenorphine-Naloxone Initiation in Emergency Departments

NCT03821103
View directory record Official record
Conditions
Opioid Use
Interventions
Training, Behavioral economic enhanced arm
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Phase 2 Interventional

Buprenorphine Combination Tablet Feasibility - 1

NCT00000298
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 30, 2026, 4:44 AM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

NCT05011266
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Rockville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 30, 2026, 4:44 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes

NCT03923374
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Use, Unspecified, Buprenorphine Dependence
Interventions
Subutex / Buprenorphine, Fetal & Neonatal MRI, DNA/Genetic/Pharmacokenetic Blood Draws
Drug · Diagnostic Test
Lead sponsor
Senthil Sadhasivam
Other
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 30, 2026, 4:44 AM EDT
Withdrawn Phase 3 Interventional

Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back Pain

NCT01431742
View directory record Official record
Conditions
Pain, Low Back Pain
Interventions
BEMA Buprenorphine
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 30, 2026, 4:44 AM EDT
Not listed Not applicable Interventional

Improving Office Based Treatment of Opioid Use Disorder With Technology

NCT03586466
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
BupreCare, Buprenorphine/naloxone, MEMS
Device · Drug · Other
Lead sponsor
MedicaSafe, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
San Diego, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Phase 4 Interventional Results available

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

NCT04995029
View directory record Official record
Conditions
Moderate to Severe Opioid-use Disorder
Interventions
Transmucosal Buprenorphine, Extended-release Buprenorphine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
785 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
28
States / cities
Garden Grove, California • Panorama City, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Not applicable Interventional Results available

OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

NCT04948307
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
OXD01 digital therapy, Standard of Care
Device · Other
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Oceanside, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 30, 2026, 4:44 AM EDT
Completed Phase 3 Interventional Results available

Opiate Suicide Study in Patients With Major Depression

NCT04116528
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 4:44 AM EDT
Recruiting Early Phase 1 Interventional

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

NCT06726200
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine + naloxone (Suboxone), Buprenorphine Injection
Drug
Lead sponsor
Rachel R. Luba
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 30, 2026, 4:44 AM EDT